Treatment of Primary Urethral Carcinoma of the Distal Urethra in Female Patients (Stage Ta–T2, N0)

Clinical scenario

This protocol applies to female patients with primary urethral carcinoma confined to the distal urethra, presenting at pathological stage Ta through T2, with no regional lymph node involvement (N0) and no distant metastasis (M0).

Female Distal urethra Stage Ta–T2 N0, M0

Treatment approach (overview)

For this patient group, management centres on achieving local disease control through either a surgical or a radiotherapy-based strategy. The surgical approach may involve radical resection of the urethra and surrounding tissue, while organ-preserving surgery represents an alternative under specific intra-operative conditions.

Local radiotherapy is also an established option, with external beam techniques used alone or in combination with brachytherapy, though local toxicity must be discussed with the patient.

The complete evidence-based regimen — including selection criteria between approaches, technique specifics, and follow-up — is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

To provide the highest chance of local cure in females with localised urethral carcinoma, primary radical urethrectomy should include removal of all the periurethral tissue from the bulbocavernosus muscle, bilaterally and distally, with a cylinder of all adjacent soft tissue up to the pubic symphysis and bladder neck.
Offer radical urethrectomy unless specific criteria for organ preservation are met.
Offer urethra-sparing surgery as an alternative to primary urethrectomy to females with distal urethral tumours if negative surgical margins can be achieved intra-operatively.
Offer local radiotherapy as an alternative to urethral surgery to females with localised urethral tumours but discuss local toxicity.
With a median cumulative dose of 65 Gy (range 40–106 Gy), the five-year local control rate was 64% and seven-year CSS was 49%.
In one study, the addition of brachytherapy to EBRT reduced the risk of local recurrence by a factor of 4.2.

View source ↗